Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures

Trial Profile

Phase 2 Double-blind,Placebo-controlled Study for Evaluation of Efficiency, Safety,Tolerance and Pharmacokinetics of Different Doses of Remegal in Additional Therapy for Patients With Refractory Partial Seizures

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Beprodone (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Valexfarm
  • Most Recent Events

    • 05 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Aug 2010 New trial record
    • 09 Sep 2009 According to a Marco Polo Pharmaceuticals media release, its subsidiary Valexpharm Ltd. has received permission to perform a Phase IIa clinical trial of VLB 01 from the Russian Federal Service on Surveillance In Healthcare and Social Development.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top